Loading
Dauntless Biotherapeutics
Dauntless Biotherapeutics is a San Diego area company developing an antibody that carries a drug to cancer cells, aimed at cancers with few treatment options.
Also called: DAUNTLESS BIOTHERAPEUTICS, INC.
Overview
Dauntless Biotherapeutics, Inc. is a private preclinical oncology company developing an antibody-drug conjugate against an undisclosed tumour-associated antigen; its website says it is raising a seed round for lead optimisation, in vivo and non-GLP toxicity studies before an investigational new drug filing. In fiscal year 2026 the National Cancer Institute funded its SBIR project on a dual-function antibody therapeutic to overcome breast cancer resistance (1R43CA306683-01A1, USD 400,000).
Headquarters
San Diego, CA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR Phase I (R43) award 1R43CA306683-01A1: Overcoming Breast Cancer Resistance with a Dual-Function Antibody Therapeutic | 2026 | $400K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Notes
- NIH RePORTER gives San Diego; the website gives an address in Carlsbad, California. Read on 4 November 2026. The site names no product.
Connected
3cancers
fronts
technologies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
dauntlessbiotherapeutics.com · 1
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/